Case number 2017-1079
Takeda Pharmaceutical Company v. Array BioPharma Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | TAKEDA PHARMACEUTICAL COMPANY v. ARRAY BIOPHARMA INC. [OPINION] [nonprecedential] (0) |
| Feb 1, 2018 | 50 | Mandate issued to the United States Patent and Trademark Office. Costs taxed in the amount of $1651.52. Service as of this date by Clerk of Court. [494327] [JAB] [Entered: 02/01/2018 10:43 AM] (0) |
| Jan 8, 2018 | 49 | Bill of Costs for Appellant Takeda Pharmaceutical Company Limited. Service: 01/08/2018 by email. Objection to Bill of Costs due on 01/22/2018. [488080] [Stephen Maebius] [Entered: 01/08/2018 04:33 PM] (0) |
| Dec 26, 2017 | 48 | OPINION and JUDGMENT filed. The judgment or decision is: Vacated and Remanded. (Nonprecedential Opinion). (For the Court: Moore,Circuit Judge; O'Malley,Circuit Judge and Wallach,Circuit Judge). [485464] [JAB] [Entered: 12/26/2017 09:29 AM] (0) |
| Dec 11, 2017 | 47 | Submitted after ORAL ARGUMENT by Stephen Maebius for Takeda Pharmaceutical Company Limited and Thomas J. Meloro for Array BioPharma Inc. Panel: Judge: Moore , Judge: O'Malley , Judge: Wallach. [481519] [JAB] [Entered: 12/11/2017 11:03 AM] (0) |
| Nov 13, 2017 | 46 | Response to oral argument order from the Appellee Array BioPharma Inc.. designating Thomas J. Meloro as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [474544] [Thomas Meloro] [Entered: 11/10/2017 02:27 PM] (0) |
| Nov 8, 2017 | 45 | Response to oral argument order from the Appellant Takeda Pharmaceutical Company Limited. designating Stephen B. Maebius as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [474003] [Stephen Maebius] [Entered: 11/08/2017 12:02 PM] (0) |
| Oct 20, 2017 | 44 | NOTICE OF CALENDARING. Panel: 1712Q. Case scheduled Dec 11, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 402. Response to oral argument order due: 11/15/2017. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [469471] [JAB] [Entered: 10/20/2017 01:25 PM] (0) |
| Jun 5, 2017 | 42 | Notice from Appellant Takeda Pharmaceutical Company Limited regarding conflicts with oral argument (August 7, 2017 September 5-8, 2017). Service: 06/05/2017 by email. [436270] [Stephen Maebius] [Entered: 06/05/2017 11:23 AM] (0) |
| Jun 5, 2017 | 43 | 6 paper copies of the Corrected Appendix Brief in 2 volumes [39] received from Appellant Takeda Pharmaceutical Company Limited. [436467] [CMP] [Entered: 06/05/2017 04:29 PM] (0) |
| Jun 2, 2017 | 41 | Notice from Appellee Array BioPharma Inc. regarding conflicts with oral argument (August 7-10, 2017; September 8, 2017). Service: 06/02/2017 by email. [436092] [Thomas Meloro] [Entered: 06/02/2017 03:30 PM] (0) |
| May 26, 2017 | 40 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks [AUG, SEP, OCT], or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. [434619] [MJL] [Entered: 05/26/2017 03:54 PM] (0) |
| May 26, 2017 | 39 | CORRECTED APPENDIX FILED for Takeda Pharmaceutical Company Limited [38]. Number of Pages: 933. Service: 05/26/2017 by email. The paper copies of the appendix should be received by the court on or before 06/05/2017. [434615] [MJL] [Entered: 05/26/2017 03:49 PM] (933) |
| May 26, 2017 | 38 | TENDERED from Appellant Takeda Pharmaceutical Company Limited. Title: CORRECTED JOINT APPENDIX. Service: 05/26/2017 by email. [434577] [Stephen Maebius] [Entered: 05/26/2017 03:05 PM] (933) |
| May 26, 2017 | 37 | **TEXT ONLY** ORDER granting motion to withdraw attorney [36] filed by Appellant Takeda Pharmaceutical Company Limited. Philippe Y. Riesen is withdrawn as counsel for Appellant. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [434464] [MJL] [Entered: 05/26/2017 12:17 PM] (0) |
| May 26, 2017 | 36 | MOTION of Appellant Takeda Pharmaceutical Company Limited to withdraw counsel Philippe Y. Riesen. Any response is due within 10 days of service [Consent: unopposed]. Service: 05/26/2017 by email. [434445] [Stephen Maebius] [Entered: 05/26/2017 11:58 AM] (4) |
| May 23, 2017 | 35 | NOTICE OF REJECTION: The appendix of Appellant Takeda Pharmaceutical Company Limited [33] is not in compliance with the rules of this court and is therefore rejected for filing. Corrected appendix due 06/06/2017. Service as of this date by Clerk of Court. [433407] [MJL] [Entered: 05/23/2017 09:31 AM] (2) |
| May 22, 2017 | 34 | Certificate of Compliance with Fed. Cir. R. 17 (Agency) for Appellant Takeda Pharmaceutical Company Limited. Service: 05/22/2017 by email. [433290] [Stephen Maebius] [Entered: 05/22/2017 04:37 PM] (3) |
| May 22, 2017 | 33 | TENDERED from Appellant Takeda Pharmaceutical Company Limited. Title: JOINT APPENDIX. Service: 05/22/2017 by email. [433273]. This appendix has been rejected. See Doc. No. [35]. [Stephen Maebius] [Entered: 05/22/2017 04:17 PM] (0) |
| May 22, 2017 | 32 | Certificate of Compliance with Fed. Cir. R. 17 (Agency) for Appellee Array BioPharma Inc.. Service: 05/22/2017 by email. [433248] [Michael Johnson] [Entered: 05/22/2017 03:27 PM] (3) |
| May 22, 2017 | 31 | Statement of Compliance with Fed. Cir. R. 33 for Appellant Takeda Pharmaceutical Company Limited and Appellee Array BioPharma Inc.. Service: 05/22/2017 by email. [433239] [Stephen Maebius] [Entered: 05/22/2017 03:16 PM] (3) |
| May 17, 2017 | 30 | 6 paper copies of the Reply Brief [29] received from Appellant Takeda Pharmaceutical Company Limited. [432350] [KW] [Entered: 05/17/2017 04:12 PM] (0) |
| May 15, 2017 | 29 | REPLY BRIEF FILED for Appellant Takeda Pharmaceutical Company Limited [28]. Number of Pages: 15. Service: 05/15/2017 by email. The paper copies of the brief should be received by the court on or before 05/22/2017. Appendix due 05/22/2017. [431458] [MJL] [Entered: 05/15/2017 03:04 PM] (22) |
| May 15, 2017 | 28 | TENDERED from Appellant Takeda Pharmaceutical Company Limited. Title: REPLY BRIEF. Service: 05/15/2017 by email. [431384] [Stephen Maebius] [Entered: 05/15/2017 01:03 PM] (22) |
| May 1, 2017 | 27 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [26] filed by Appellant Takeda Pharmaceutical Company Limited. Reply brief is due 05/15/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [428295] [CMP] [Entered: 05/01/2017 03:39 PM] (0) |
| May 1, 2017 | 26 | MOTION of Appellant Takeda Pharmaceutical Company Limited to extend the time to 05/15/2017 to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 05/01/2017 by email. [428271] [Stephen Maebius] [Entered: 05/01/2017 02:55 PM] (5) |
| Apr 27, 2017 | 25 | 6 paper copies of the Response Brief [23] received from Appellee Array BioPharma Inc. [427616] [KW] [Entered: 04/27/2017 03:25 PM] (0) |
| Apr 25, 2017 | 24 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: SECOND Notice regarding the ECF account of Mr. Philippe Yoland Riesen, Esq. for Takeda Pharmaceutical Company Limited. The e-mail address, (philippe.riesen@hoganlovells.com), associated with your CM/ECF account has generated a delivery failure notice. Counsel should promptly report a change in contact information with the Pacer Service Center (see Fed. Cir. R. 47.3(c)(1). If the attorney is no longer associated with the case, counsel should promptly move to withdraw the attorney (see Fed. Cir. R. 47.3(c)(5)). [426965] [PMM] [Entered: 04/25/2017 02:38 PM] (0) |
| Apr 24, 2017 | 22 | TENDERED from Appellee Array BioPharma Inc.. Title: RESPONSE BRIEF. Service: 04/24/2017 by email. [426725] [Thomas Meloro] [Entered: 04/24/2017 05:43 PM] (51) |
| Apr 24, 2017 | 23 | BRIEF FILED for Appellee Array BioPharma Inc. [22]. Number of Pages: 44. Service: 04/24/2017 by email. The paper copies of the brief should be received by the court on or before 05/02/2017. Appellant Takeda Pharmaceutical Company Limited's reply brief is due 05/08/2017. [426964] [MJL] [Entered: 04/25/2017 02:35 PM] (51) |
| Apr 3, 2017 | 20 | MOTION of Appellee Array BioPharma Inc. to extend the time to 04/24/2017 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 04/03/2017 by email. [421028] [Michael Johnson] [Entered: 04/03/2017 03:20 PM] (5) |
| Apr 3, 2017 | 21 | **TEXT ONLY** ORDER granting motion to extend time to file appellee's response brief [20] filed by Appellee Array BioPharma Inc.. The brief is due 04/24/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [421038] [MJL] [Entered: 04/03/2017 03:40 PM] (0) |
| Mar 3, 2017 | 19 | 6 paper copies of the Opening Brief [17] received from Appellant Takeda Pharmaceutical Company Limited. [412413] [KW] [Entered: 03/03/2017 02:42 PM] (0) |
| Mar 2, 2017 | 18 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account of Mr. Philippe Yoland Riesen, Esq. for Takeda Pharmaceutical Company Limited. The e-mail address, (philippe.riesen@hoganlovells.com), associated with your CM/ECF account has generated a delivery failure notice. Counsel should promptly report a change in contact information with the Pacer Service Center (see Fed. Cir. R. 47.3(c)(1). If the attorney is no longer associated with the case, counsel should promptly move to withdraw the attorney (see Fed. Cir. R. 47.3(c)(5)). [411959] [PMM] [Entered: 03/02/2017 12:31 PM] (0) |
| Mar 1, 2017 | 16 | TENDERED from Appellant Takeda Pharmaceutical Company Limited. Title: OPENING BRIEF. Service: 03/01/2017 by email. [411794] [Stephen Maebius] [Entered: 03/01/2017 07:23 PM] (298) |
| Mar 1, 2017 | 17 | BRIEF FILED for Appellant Takeda Pharmaceutical Company Limited [16]. Number of Pages: 40. Service: 03/01/2017 by email. The paper copies of the brief should be received by the court on or before 03/09/2017. Appellee Array BioPharma Inc.'s brief is due 04/10/2017. [411843] [MJL] [Entered: 03/02/2017 09:16 AM] (298) |
| Mar 1, 2017 | 15 | Entry of appearance for Philippe Y. Riesen as of counsel for Appellant Takeda Pharmaceutical Company Limited. Service: 03/01/2017 by email. [411562] [Stephen Maebius] [Entered: 03/01/2017 10:32 AM] (1) |
| Jan 23, 2017 | 14 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The motion [12] filed by Appellant did not include the required certificate of interest. CORRECTION: For future motions, please ensure a certificate of interest is attached. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [400614] [MJL] [Entered: 01/23/2017 08:48 AM] (0) |
| Jan 23, 2017 | 13 | **TEXT ONLY** ORDER granting motion to extend time to file the appellant's principal brief [12] filed by Appellant Takeda Pharmaceutical Company Limited. The brief is due 03/01/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [400612] [MJL] [Entered: 01/23/2017 08:47 AM] (0) |
| Jan 23, 2017 | 12 | MOTION of Appellant Takeda Pharmaceutical Company Limited to extend the time to 03/01/2017 at 11:59 pm to file the appellant/petitioner's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/20/2017 by email. [400570] [Stephen Maebius] [Entered: 01/20/2017 01:35 PM] (7) |
| Jan 23, 2017 | 11 | Certificate of Interest for the Appellant Takeda Pharmaceutical Company Limited. Service: 01/20/2017 by email. [400569] [Stephen Maebius] [Entered: 01/20/2017 01:01 PM] (1) |
| Nov 29, 2016 | 10 | Certified list from the United States Patent and Trademark Office. Service: 11/29/2016 by email. Appellant's brief is due 01/30/2017. [386769] [MJL] [Entered: 11/29/2016 01:44 PM] (57) |
| Nov 3, 2016 | 9 | Entry of appearance for Stephen B. Maebius as principal counsel for Appellant Takeda Pharmaceutical Company Limited. Service: 11/03/2016 by email. [380094] [Stephen Maebius] [Entered: 11/03/2016 01:14 PM] (1) |
| Nov 3, 2016 | 8 | Certificate of Interest for the Appellant Takeda Pharmaceutical Company Limited. Service: 11/03/2016 by email. [380092] [Stephen Maebius] [Entered: 11/03/2016 01:09 PM] (1) |
| Nov 3, 2016 | 7 | Docketing Statement for the Appellant Takeda Pharmaceutical Company Limited. Service: 11/03/2016 by email. [380090] [Stephen Maebius] [Entered: 11/03/2016 01:08 PM] (3) |
| Nov 3, 2016 | 6 | Certificate of Interest for the Appellee Array BioPharma Inc.. Service: 11/03/2016 by email. [380062] [Thomas Meloro] [Entered: 11/03/2016 12:07 PM] (2) |
| Nov 3, 2016 | 5 | Docketing Statement for the Appellee Array BioPharma Inc.. Service: 11/03/2016 by email. [380061] [Thomas Meloro] [Entered: 11/03/2016 12:06 PM] (3) |
| Nov 3, 2016 | 4 | Entry of appearance for Alexandra F. Awai as of counsel for Appellee Array BioPharma Inc.. Service: 11/03/2016 by email. [380057] [Alexandra Awai] [Entered: 11/03/2016 12:04 PM] (2) |
| Nov 3, 2016 | 3 | Entry of appearance for Michael W. Johnson as of counsel for Appellee Array BioPharma Inc.. Service: 11/03/2016 by email. [380054] [Michael Johnson] [Entered: 11/03/2016 11:59 AM] (2) |
| Nov 3, 2016 | 2 | Entry of appearance for Thomas J. Meloro as principal counsel for Appellee Array BioPharma Inc.. Service: 11/03/2016 by email. [380052] [Thomas Meloro] [Entered: 11/03/2016 11:56 AM] (2) |
| Oct 20, 2016 | 1 | Appeal docketed. Received: 10/13/2016. [376262] Entry of Appearance due 11/03/2016. Certificate of Interest due 11/03/2016. Docketing Statement due 11/03/2016. Certified List due 11/29/2016. [MJL] [Entered: 10/20/2016 02:30 PM] (8) |
